```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "A",
          "alt": "G",
          "position": "244"
        },
        "variant_string_id": "PINK1 A244G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Homozygous or compound heterozygous mutations in the PINK1 gene represent the second most frequent cause of autosomal recessive parkinsonism after Parkin.  Wild-type but not mutant PINK1 has been shown to protect cells from staurosporine-induced apoptosis.",
          "judgment": "Yes",
          "reasoning": "PINK1 mutations are linked to autosomal recessive parkinsonism. The paper aims to show that the mutations abolish the protective effect of wild-type PINK1 against staurosporine-induced apoptosis, thus contributing to disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Wild-type but not mutant PINK1 has been shown to protect cells from staurosporine-induced apoptosis. We adopted the same experimental setting to test the functional effect of the two mutant forms on cell viability (Fig. 1). TUNEL assay and measurement of active caspase-3 were used to quantify apoptosis.",
          "judgment": "Yes",
          "reasoning": "The assay (apoptosis detection via TUNEL and caspase-3 activation) is applicable to the disease mechanism as loss of PINK1 function increases apoptosis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Cells were transiently transfected with pcDNA3 expression vectors encoding the wild-type or mutant proteins, or with the empty vector (control), using Lipofectamine 2000 (Invitrogen).",
          "judgment": "Yes",
          "reasoning": "The experiment included both normal/negative/wild-type control and abnormal/positive/null control (empty vector).",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "No known pathogenic or benign variants were used as controls. Only wild type and empty vector controls were used.",
          "judgment": "No",
          "reasoning": "The experiment only used wild type and empty vector controls. It did not include known pathogenic or benign variants.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "After staurosporine treatment, cells overexpressing PINK1Wt showed significantly lower levels of apoptosis when compared to control cells [TUNEL-positive cells: (26.9 ± 1.7)% vs. (36.0 ± 1.4)%, P < 0.001]. In contrast, no significant difference in cell viability was observed between cells overexpressing PINK1A244G or PINK1V317I and controls [TUNEL-positive cells: (33.3 ± 1.6)% and (35.7 ± 1.6)% vs. (36.0 ± 1.4%)]",
          "judgment": "No",
          "reasoning": "P value is reported, but OddsPath is not calculated and there is insufficient data to calculate it.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "No pathogenic or benign variant controls were used across the study.",
          "judgment": "No",
          "reasoning": "No known benign or pathogenic variant controls were used in the study. Therefore, the number of benign/pathogenic controls is 0, which is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "PINK1 A244G abolishes the protective effect of wild-type PINK1 against staurosporine-induced apoptosis. Since no pathogenic controls were used, the strength of evidence is PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "V",
          "alt": "I",
          "position": "317"
        },
        "variant_string_id": "PINK1 V317I"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Homozygous or compound heterozygous mutations in the PINK1 gene represent the second most frequent cause of autosomal recessive parkinsonism after Parkin.  Wild-type but not mutant PINK1 has been shown to protect cells from staurosporine-induced apoptosis.",
          "judgment": "Yes",
          "reasoning": "PINK1 mutations are linked to autosomal recessive parkinsonism. The paper aims to show that the mutations abolish the protective effect of wild-type PINK1 against staurosporine-induced apoptosis, thus contributing to disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Wild-type but not mutant PINK1 has been shown to protect cells from staurosporine-induced apoptosis. We adopted the same experimental setting to test the functional effect of the two mutant forms on cell viability (Fig. 1). TUNEL assay and measurement of active caspase-3 were used to quantify apoptosis.",
          "judgment": "Yes",
          "reasoning": "The assay (apoptosis detection via TUNEL and caspase-3 activation) is applicable to the disease mechanism as loss of PINK1 function increases apoptosis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Cells were transiently transfected with pcDNA3 expression vectors encoding the wild-type or mutant proteins, or with the empty vector (control), using Lipofectamine 2000 (Invitrogen).",
          "judgment": "Yes",
          "reasoning": "The experiment included both normal/negative/wild-type control and abnormal/positive/null control (empty vector).",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "No known pathogenic or benign variants were used as controls. Only wild type and empty vector controls were used.",
          "judgment": "No",
          "reasoning": "The experiment only used wild type and empty vector controls. It did not include known pathogenic or benign variants.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "After staurosporine treatment, cells overexpressing PINK1Wt showed significantly lower levels of apoptosis when compared to control cells [TUNEL-positive cells: (26.9 ± 1.7)% vs. (36.0 ± 1.4)%, P < 0.001]. In contrast, no significant difference in cell viability was observed between cells overexpressing PINK1A244G or PINK1V317I and controls [TUNEL-positive cells: (33.3 ± 1.6)% and (35.7 ± 1.6)% vs. (36.0 ± 1.4%)]",
          "judgment": "No",
          "reasoning": "P value is reported, but OddsPath is not calculated and there is insufficient data to calculate it.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "No pathogenic or benign variant controls were used across the study.",
          "judgment": "No",
          "reasoning": "No known benign or pathogenic variant controls were used in the study. Therefore, the number of benign/pathogenic controls is 0, which is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "PINK1 V317I abolishes the protective effect of wild-type PINK1 against staurosporine-induced apoptosis. Since no pathogenic controls were used, the strength of evidence is PS3_supporting."
    }
  ]
}
```